Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch
Stallergenes Greer, a biopharmaceutical company specialising in the diagnosis and treatment of respiratory allergies, announced today the initiation of a Phase III clinical study (YOBI, YOung patients and BIrch allergy) to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis with or without asthma. The randomised, double-blind placebo-controlled Phase III study will involve approximately 80 sites in 12 European countries.
Allergic rhino-conjunctivitis is a worldwide disease and a global health burden affecting more than 500 million people, who are at higher risk of developing rhinitis exacerbation and asthma than the general population1..Birch is among the strongest allergy-producing trees in northern Europe. The allergic potential of other trees belonging to the birch homologous group, such as alder and hazel, is also increasing steadily2.
In children and adolescents, allergic rhino-conjunctivitis can lead to sleep problems, fatigue, missed school days and can complicate outdoor activities3. Individuals sensitised at a young age are also more at risk of developing asthma. The younger the children are, the higher their risk of developing asthma, which highlights the relevance of early causal treatment in paediatric patients to slow the worsening of allergy symptoms4. Allergen immunotherapy (AIT) is currently the only available therapeutic treatment that has the potential to uniquely alter the natural course of the disease5. In its liquid form, sublingual AIT can provide a needle-free and flexible treatment for children and adolescents.
“Allergic rhino-conjunctivitis induced by birch and related trees can lead to a spiraling of respiratory symptoms and conditions in the paediatric population. The YOBI study will contribute to addressing a global health burden, while deepening our knowledge of AIT with the aim of improving patient outcomes for children and adolescents with birch-induced allergies,” said Professor Oliver Pfaar, International Coordinator of the YOBI study, Head of Rhinology and Allergy, Department of Otorhinolaryngology, Philipps-Universität Marburg, Germany.
“Stallergenes Greer’s AIT treatments have proven their efficacy and safety in both clinical trials and the real world, ” stated Michele Antonelli, CEO of Stallergenes Greer. “ This paediatric Phase III study, illustrates our determination to further develop evidence-based solutions and build on robust datasets and cutting-edge research technologies to advance precision medicine combined with dose adaptation for the benefit of patients with allergies, the medical community, and health systems.”
ABOUT STALORAL ®
Staloral® is a sublingual solution of allergen extracts for AIT. It is indicated in the treatment of seasonal or perennial allergic rhinitis, rhino-conjunctivitis and mild to moderate allergic asthma in adults and, in certain territories, in the paediatric population (children over 5 years of age).
Clinical evidence of the efficacy of Staloral® is globally consistent over the clinical studies Stallergenes Greer conducted versus placebo. The effectiveness of Staloral® as a causal treatment for allergic rhino-conjunctivitis beyond clinical trials was also assessed by Stallergenes Greer’s real-world studies EfficAPSI and BREATH (Bringing Real-World Evidence to Allergy Treatment for Health).
ABOUT ALLERGIC RHINITIS/ALLERGIC RHINO-CONJUNCTIVITIS
Allergic rhinitis/allergic rhino-conjunctivitis (AR/ARC) is a chronic disorder of the upper airways that is caused by allergen exposure and the resulting IgE-mediated inflammation of the nose and, to a less extent, the eyes. Allergic rhinitis can notably include symptoms such as sneezing, a runny nose, wheezing, cough, itching, and watery/itchy eyes. Symptoms may be severe and significantly impact the patient’s quality of life, as well as worsen over time with progression towards asthma4.
First intention symptomatic treatments such as antihistamines and nasal corticosteroids provide temporary relief to patients. The primary therapeutic goals of AIT include reducing symptoms, reducing symptomatic medication use, and improving allergy-related quality of life. AIT achieves these goals and can alter the course of the disease, with benefits persisting in many patients for several years after treatment discontinuation6.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1. Bousquet, J., et al., Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy, 2008. 63 Suppl 86: p. 8-160.
2. Biedermann, T., et al., Birch pollen allergy in Europe. Allergy, 2019. 74(7): p. 1237-1248.
3. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62 Suppl 85:17-25. doi:10.1111/j.1398-9995.2007.01549.x
4. Klimek, L., et al., ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo journal international, 2019. 28(7): p. 255-276.
5. Roberts G, Pfaar O, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798. doi:10.1111/all.13317
6. Hesse, L., et al., Allergen immunotherapy for allergic airway diseases: Use lessons from the past to design a brighter future. Pharmacology & Therapeutics, 2022: p. 108115.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005458/en/
Contact information
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT and E.ON Extend Partnership to Drive AI-Powered Energy Management Innovation11.11.2025 03:00:00 EET | Press release
Global technology and IT services provider FPT and E.ON Optimum, the digital solutions arm of E.ON UK, under E.ON Group, announced a new agreement to extend their collaboration in digital energy management. The signing marks the next phase of a partnership established in 2022, reaffirming both corporations’ shared vision of harnessing technology to accelerate innovation and sustainability in the energy sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110039775/en/ FPT and E.ON Optimum leaders at the signing ceremony to extend their partnership in AI-powered energy management. Under this agreement, FPT will continue to support the development and operation of E.ON Optimum’s solution platform, a cloud-based energy management system that gives business energy users timely, flexible data analysis, allowing for better and faster decisions on net-zero energy usage. The next phase focuses on maintaining and enhancing web a
Ant International Open Sources Time-Series Transformer AI Model to Enable More Businesses to Benefit from AI-Powered Forecasting11.11.2025 02:30:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has released its proprietary Falcon TST (Time-Series Transformer) AI model, the industry-first Mixture of Experts architecture-based big data model with multiple patch tokenizers, supported by up to 2.5 billion parameters. The model has also achieved state-of-the-art zero-shot results on well-acknowledged long-term forecasting benchmarks, such as absolute mean error rates. Deployed internally at Ant International to manage cashflow and FX exposure on an hourly, daily and weekly basis, Falcon TST has achieved accuracy rates of over 90%, and cut the company’s FX costs by up to 60%. Ant International also collaborated with various industry partners to deploy the model in different use cases, such as in helping businesses mitigate FX cost and volatility, as well as to support airlines in offering more stable, competitive pricing to their customers. With the Airports Council International W
The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100 th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More11.11.2025 01:08:00 EET | Press release
The Empire State Building (ESB) today announced its Holiday Celebration plans include: holiday décor, classic movie screenings, local pop-ups, festive tower lightings, and a holiday takeover with the Radio City Rockettes to celebrate the most wonderful time of the year at New York City’s number one attraction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110124149/en/ The Empire State Building Holiday Celebrations Include: Radio City Rockettes 100th Anniversary Exhibits, Visits from Santa, Holiday Décor, Movie Screenings, Pop-ups, Lightings, and More “There is no better place to celebrate the holidays in New York City than at the Empire State Building Observatory,” said Dan Rogoski, General Manager at the Empire State Building Observatory. “This year, New Yorkers and visitors will enjoy the best of the holiday season in our iconic venue as we celebrate 100 years of the Radio City Rockettes.” Deck the Halls From the grou
Megaport to Acquire Latitude.sh, Creating an Industry-leading Compute and Network-as-a-Service Platform to Power High-performance Applications and AI Workloads Globally11.11.2025 00:17:00 EET | Press release
Megaport Limited (ASX: MP1), the world’s leading Network-as-a-Service (NaaS) provider, today announced it has entered into an agreement to acquire Latitude.sh, a leading global Compute-as-a-Service company delivering high-performance CPU and GPU infrastructure on demand. Following completion of the acquisition, the combined capabilities will create a global platform that unites Megaport’s private, high-speed connectivity fabric with Latitude.sh’s compute infrastructure, enabling enterprises to rapidly deploy and connect critical workloads across more than 1,000 data centres in 26 countries. “Megaport has long been trusted by the world’s largest enterprises to move workloads seamlessly between data centers and the cloud,” said Michael Reid, CEO of Megaport. “By bringing Latitude.sh into the fold, we’re extending that promise beyond the network, and into high-performance, optimized compute, complementing cloud providers. Together, we will not only serve the massive traditional compute ma
Svante and Södra Launch EU-Based Carbon Capture Pilot to Advance Biogenic CO₂ Utilization10.11.2025 23:49:00 EET | Press release
Svante Technologies Inc. (“Svante”), a global leader in solid sorbent-based carbon capture and removal solutions, is proud to share that Södra, Sweden’s largest forest-owner association, has announced it will test Svante’s carbon capture technology at the Värö industrial site in early 2026 and evaluate opportunities for large-scale capture in the future. This pilot project marks Svante’s first deployment in the EU forestry sector and represents a significant step toward scaling biogenic carbon capture in pulp and paper production. The pilot will evaluate the performance of Svante’s proprietary solid sorbent filters in capturing biogenic CO₂ emissions from Södra’s pulp operations, with the goal of enabling new circular value chains and supporting Sweden’s climate targets. A Strategic Step Toward Circular Bioeconomy Södra’s pulp production generates biogenic CO₂, which is a renewable carbon source with potential applications across food, water purification, chemical manufacturing, and e-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom